Protagonist Therapeutics to Present Phase 2 Study Data at ASH Meeting

Protagonist Therapeutics, Inc. will present the final data from its Phase 2 REVIVE study on rusfertide at the 66th Annual American Society of Hematology (ASH) Meeting. The event will be held from December 7-10, 2024, in San Diego. Aaron Gerds, MD from Cleveland Clinic will present the findings, focusing on rusfertide as a treatment for polycythemia vera. The presentation is scheduled for December 9, at the San Diego Convention Center.

The company's pipeline includes JNJ-2113, an IL-23 receptor antagonist in Phase 3 development for psoriasis. Rusfertide, a hepcidin mimetic, is in Phase 3 for polycythemia vera and is being developed in collaboration with Takeda Pharmaceuticals.